Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Shows Increasing Demand To Be Observed In The Coming Decade

Key players in the global autologous stem cell and non-stem cell based therapies market are investing heavily in their research and development activities so as to gain an upper hand in the market. Some of the major players operating in the market are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. 

Key players operating in the market has robust pipeline of autologous stem cell and non-stem cell based therapies, which is expected to drive market over the forecast period. For instance in November 2019, Caladrius Biosciences (previously known NeoStem, Inc) announced positive results of CD34+ cell therapy CLBS16 from the ESCaPE-CMD Trial as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women.

Moreover Major players in the industry are investing in the development of innovative and new products, in order strengthening their position in autologous stem cell and non-stem cell based therapies market. For instance in February 2018, MEDIPOST announced that the U.S. Food and Drug Administration has approved its stem cell-based Alzheimer’s disease drug, NEUROSTEM for clinical trials.

Read More: https://www.blogger.com/blog/post/preview/8474931090123965692/19288652286508012